skin disease: Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.
Acquired keratosis [keratoderma] palmaris et plantaris
DOID EFO Endpoint Browser PheWeb
L12_ACQKERAT
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
161 |
4. Check minimum number of eventsNone |
161 |
5. Include endpointsNone |
161 |
6. Filter based on genotype QC (FinnGen only) |
154 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L85
- Name in latin
- Keratosis (keratoderma) palmaris et plantaris acquisita
Similar endpoints
↥List of similar endpoints to
Acquired keratosis [keratoderma] palmaris et plantaris
based on the number of shared cases.
Similar with more cases:
- Other epidermal thickening
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1124 | 601 | 516 |
| Only index persons | 982 | 536 | 446 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 54.60 | 57.17 | 51.70 |
| Only index persons | 54.36 | 56.87 | 51.33 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 154 | 84 | 70 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 55.70 | 57.15 | 53.96 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 161
- Matched controls
- 1610
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L85.1
ICD-10 Finland
Acquired keratosis [keratoderma] palmaris et plantaris
+∞
187.0
141
*
D05BB02
ATC
acitretin; oral
62.5
98.0
57
14
D07XC01
ATC
betamethasone; topical
20.3
85.7
91
97
D02AE01
ATC
carbamide; topical
13.4
43.1
47
48
E0000UV, ,
ATC
9.2
37.7
125
440
D07AD01
ATC
clobetasol; topical
8.1
37.0
69
137
XQ802
NOMESCO Finland
Epicutan test
12.3
26.1
28
27
L30.9
ICD-10 Finland
Dermatitis, unspecified
5.7
25.7
68
182
D07AC01
ATC
betamethasone; topical
5.3
24.5
99
374
E000003, ,
ATC
9.9
21.7
27
32
D07AC13
ATC
mometasone; topical
4.4
19.3
81
302
D05AX52
ATC
calcipotriol, combinations; topical
7.2
15.0
24
38
E000006, ,
ATC
6.0
14.0
27
52
L30.8
ICD-10 Finland
Other specified dermatitis
15.9
13.2
21
15
E000001, ,
ATC
3.8
13.0
52
180
D05AX02
ATC
calcipotriol; topical
12.0
12.7
23
22
D07BC01
ATC
betamethasone and antiseptics; topical
4.4
12.2
35
95
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
4.1
11.7
37
108
7011A
ICD-9 Finland
Other hypertrophic and atrophic conditions of skin, Keratoderma, acquired[KERATODERMA PALMARE ET PLANTARE ACQUISITUM]
+∞
11.6
11
*
L85.9
ICD-10 Finland
Epidermal thickening, unspecified
+∞
11.6
11
*
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
38.0
11.5
14
*
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
4.4
11.2
32
86
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.2
11.2
25
55
TQW80
NOMESCO Finland
Local dermatologic skincare
15.2
8.9
14
10
XQ848
NOMESCO Finland
Dermatological photography
10.3
8.5
16
17
Q82.82
ICD-10 Finland
Inherited keratosis palmaris et plantaris
+∞
8.4
8
*
70110
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Keratoderma acquisitum (Kämmen, jalkapohja) (palmare, plantare)
+∞
8.4
8
*
L30.3
ICD-10 Finland
Infective dermatitis
9.6
7.7
15
17
D01AC02
ATC
miconazole; topical
4.7
7.7
19
45
D07AB02
ATC
hydrocortisone butyrate; topical
2.6
7.4
60
300
L40.0
ICD-10 Finland
Psoriasis vulgaris
6.0
6.5
17
31
D09AB01
ATC
zinc bandage without supplements; topical
15.1
6.5
10
7
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
18.9
6.3
9
5
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
20
48
4.62
8.00
2.7
2.3
—
—
—
0
0
19
47
4.45
7.31
2.7
1.7
—
—
—
0
0
52
253
2.56
6.71
4.2
3.6
922.38
179.21
ng/l
0.58
37
187
36
197
2.07
3.33
2.8
1.9
—
—
—
0
0
31
162
2.13
3.23
2.2
2.3
23.38
22.06
%
0.17
24
142
83
604
1.77
3.17
10.2
11.0
1.22
1.22
inr
0.00
31
162
56
369
1.79
2.96
2.5
3.0
513.67
952.95
ng/l
2.58
51
313
7
13
5.57
2.90
1.0
1.0
—
—
—
0
0
45
289
1.77
2.55
2.0
1.6
0.92
1.20
mg/l
0.49
37
231
11
41
2.80
2.26
1.8
1.4
1.17
1.19
g/l
0.08
11
41
44
293
1.69
2.17
2.7
2.0
1.81
3.14
mg/l
6.17
35
257
10
39
2.67
1.98
2.0
1.4
0.21
0.23
g/l
—
10
39
46
318
1.63
1.95
2.8
2.2
—
—
—
0
0
7
22
3.28
1.90
2.4
1.4
—
—
—
0
0
7
22
3.28
1.90
2.4
1.4
—
—
—
0
0
7
22
3.28
1.90
2.4
1.4
—
—
—
0
0
94
770
1.53
1.87
10.1
9.6
4.16
3.95
e9/l
0.44
79
676
5
12
4.26
1.83
1.6
1.1
—
—
—
0
0
68
523
1.52
1.80
2.2
1.9
81.66
94.57
pmol/l
1.05
30
260
76
603
1.49
1.72
2.6
2.4
—
—
—
0
0
12
56
2.23
1.65
1.3
2.0
44.50
39.60
u/l
0.29
12
49
5
14
3.65
1.62
1.0
1.1
—
—
—
0
0
7
26
2.77
1.60
3.7
1.7
24.43
25.08
mmol/l
—
7
26
6
22
2.79
1.45
2.7
1.4
—
—
—
0
0
6
23
2.67
1.38
2.7
1.3
—
—
—
0
0
6
23
2.67
1.38
2.7
1.3
—
—
—
0
0
6
23
2.67
1.38
5.8
2.3
—
—
—
0
0
6
23
2.67
1.38
5.8
2.3
—
—
—
0
0
112
983
1.46
1.38
6.3
4.0
16.10
11.86
mm/h
1.91
107
901
9
42
2.21
1.36
2.2
1.6
—
—
—
0
0
9
42
2.21
1.36
1.2
1.8
—
—
—
0
0
53
408
1.45
1.34
4.1
3.7
7.56
10.72
mg/mmol
0.31
36
242
0
41
0.00
1.33
0.0
1.2
—
—
—
0
0
0
41
0.00
1.33
0.0
1.2
—
—
—
0
0
10
48
2.16
1.30
4.6
2.8
—
—
—
0
0
143
1335
1.64
1.15
17.9
12.9
26.95
21.95
mg/l
0.87
121
1024
8
40
2.05
1.14
1.1
1.4
—
2.87
—
0
8
15
89
1.76
1.12
2.1
1.4
—
—
—
0
0
5
21
2.42
1.10
1.0
1.3
—
—
—
0
0
64
527
1.36
1.06
2.7
2.2
78.95
76.44
nmol/l
0.30
58
466
7
34
2.11
1.04
1.0
1.0
—
3.27
—
0
6
10
53
1.95
1.04
3.5
3.5
25.14
24.86
mmol/l
—
10
48
64
535
1.33
0.94
5.0
4.2
35.84
35.77
g/l
0.03
57
507
74
632
1.32
0.94
12.0
6.4
1.22
1.21
mmol/l
0.23
63
544
6
33
1.85
0.80
5.8
2.0
—
—
—
0
0
7
38
1.88
0.74
2.6
1.3
—
—
—
0
0
7
38
1.88
0.74
4.0
4.1
17.90
25.41
mg/l
—
7
30
7
38
1.88
0.74
4.0
4.1
87.17
244.45
mg/l
—
7
30
11
68
1.66
0.74
1.8
3.8
4.45
4.51
pmol/l
0.06
11
62
20
144
1.44
0.72
21.1
7.4
1.89
1.29
mmol/l
0.50
13
119
108
990
1.28
0.72
4.3
3.8
14.41
14.73
pmol/l
0.72
103
897
39
323
1.27
0.60
2.6
3.5
0.00
0.00
estimate
-0.00
11
104
31
249
1.30
0.60
1.4
1.5
—
—
—
0
0
9
61
1.50
0.55
7.0
2.8
26.27
25.04
mmol/l
—
9
61
40
337
1.25
0.54
3.6
4.6
29.18
21.24
%
1.25
11
152
139
1333
1.31
0.52
5.3
4.5
1.40
1.48
mmol/l
1.58
133
1234
8
116
0.67
0.48
2.4
3.3
—
—
—
0
0
12
161
0.72
0.43
37.3
6.4
104.67
104.27
mmol/l
0.14
12
161
5
31
1.63
0.43
1.4
1.5
—
—
—
0
0
5
31
1.63
0.43
1.4
1.5
—
—
—
0
0
5
32
1.58
0.42
1.2
2.0
—
—
—
0
0
5
32
1.58
0.42
1.4
1.4
—
—
—
0
0
28
233
1.24
0.42
1.5
1.7
866.24
1137.69
nmol/l
1.01
23
174
5
33
1.53
0.41
6.8
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
5
35
1.44
0.39
2.0
1.3
—
—
—
0
0
5
36
1.40
0.38
1.4
1.4
—
—
—
0
0
26
218
1.23
0.37
1.3
1.3
3.49
6.22
u/ml
—
8
82
70
643
1.16
0.37
2.8
3.3
0.00
0.01
estimate
0.50
13
119
70
645
1.15
0.35
3.8
4.5
0.00
0.00
estimate
-0.00
13
113
13
100
1.33
0.35
1.8
2.7
84.67
70.98
ml/min/173m2
—
6
48
89
835
1.15
0.34
3.1
2.8
—
—
—
0
0
35
306
1.18
0.33
1.7
1.5
21.69
21.44
nmol/l
0.03
28
257
10
74
1.37
0.33
1.6
1.8
—
—
—
0
0
6
47
1.29
0.32
1.5
1.7
—
—
—
0
0
17
139
1.25
0.30
3.1
1.8
—
—
—
0
0
47
517
0.87
0.30
3.3
3.5
1558.09
33.57
ng/l
0.49
31
348
130
1260
1.16
0.28
6.3
5.5
40.42
39.68
mmol/mol
0.36
124
1179
110
1141
0.89
0.25
18.7
15.8
14.93
15.13
%
0.12
110
1124
14
169
0.81
0.25
4.6
7.3
—
—
—
0
0
14
115
1.24
0.24
2.0
2.1
—
—
—
0
0
17
143
1.21
0.24
3.2
1.8
—
—
—
0
0
5
37
1.36
0.24
3.8
1.5
—
—
—
0
0
53
492
1.12
0.22
2.7
3.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
69
653
1.10
0.20
2.8
3.3
0.00
0.00
estimate
-0.00
13
104
63
595
1.10
0.19
10.3
5.5
1.21
1.22
mmol/l
0.09
56
545
11
132
0.82
0.19
2.2
1.8
—
—
—
0
0
25
226
1.13
0.16
1.5
1.3
62.87
29.69
iu/ml
0.41
12
83
49
462
1.09
0.15
4.1
3.0
—
—
—
0
0
34
366
0.91
0.15
2.6
3.0
0.59
0.43
e6/l
0.19
24
264
19
212
0.88
0.15
2.1
3.0
8.68
2.32
e6/l
—
8
114
151
1492
1.19
0.14
27.4
19.3
41.23
40.65
%
0.87
134
1407
134
1320
1.09
0.11
6.0
4.5
6.05
5.96
mmol/l
0.38
126
1221
14
126
1.12
0.09
2.1
2.2
—
—
—
0
0
21
223
0.93
0.06
1.9
2.8
2.64
0.89
e6/l
—
10
123
20
211
0.94
0.04
1.8
1.4
—
—
—
0
0
31
301
1.04
0.02
1.5
1.2
1.34
0.75
u/ml
—
9
85
128
1273
1.03
0.01
16.3
12.5
85.68
81.54
ml/min/173m2
1.30
100
1038
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
63
0.95
-0.00
2.5
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.3
—
—
—
0
0
5
54
0.92
-0.00
4.8
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.6
—
202.80
—
0
5
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
22.03
—
0
6
0
6
0.00
-0.00
0.0
4.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
12.72
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
54
0.92
-0.00
1.6
1.8
27.92
4.88
mg/l
—
5
40
Mortality – FinRegistry
↥Association
Association between endpoint L12_ACQKERAT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ACQKERAT | 1.483 [1.05, 2.09] | 0.025 |
| Birth year | 0.991 [0.98, 1.0] | 0.053 |
During the follow-up period (1.1.1998 — 31.12.2019), 57 out of 400 females with L12_ACQKERAT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ACQKERAT | 1.494 [1.12, 2.0] | 0.007 |
| Birth year | 0.987 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 297 males with L12_ACQKERAT died.
Mortality risk
Mortality risk for people of age
years, who have L12_ACQKERAT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.085% | 0.303% |
| 5 | 0.719% | 1.604% |
| 10 | 1.966% | 4.021% |
| 15 | 3.781% | 7.835% |
| 20 | 6.415% | 13.288% |
Relationships between endpoints
↥Index endpoint: L12_ACQKERAT – Acquired keratosis [keratoderma] palmaris et plantaris
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data